PMID- 33758895
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231111
DP  - 2021 Mar 12
TI  - Rapid implementation of a cohort for the study of post-acute sequelae of 
      SARS-CoV-2 infection/COVID-19.
LID - 2021.03.11.21252311 [pii]
LID - 10.1101/2021.03.11.21252311 [doi]
AB  - BACKGROUND: As the coronavirus disease 2019 (COVID-19) pandemic continues and 
      millions remain vulnerable to infection with severe acute respiratory 
      syndrome-coronavirus-2 (SARS-CoV-2), attention has turned to characterizing 
      post-acute sequelae of SARS-CoV-2 infection (PASC). METHODS: From April 21 to 
      December 31, 2020, we assembled a cohort of consecutive volunteers who a) had 
      documented history of SARS-CoV-2 RNA-positivity; b) were >/= 2 weeks past onset of 
      COVID-19 symptoms or, if asymptomatic, first test for SARS-CoV-2; and c) were 
      able to travel to our site in San Francisco. Participants learned about the study 
      by being identified on medical center-based registries and being notified or by 
      responding to advertisements. At 4-month intervals, we asked participants about 
      physical symptoms that were new or worse compared to the period prior to 
      COVID-19, mental health symptoms and quality of life. We described 4 time 
      periods: 1) acute illness (0-3 weeks), 2) early recovery (3-10 weeks), 3) late 
      recovery 1 (12-20 weeks), and 4) late recovery 2 (28-36 weeks). Blood and oral 
      specimens were collected at each visit. RESULTS: We have, to date, enrolled 179 
      adults. During acute SARS-CoV-2 infection, 10 had been asymptomatic, 125 
      symptomatic but not hospitalized, and 44 symptomatic and hospitalized. In the 
      acute phase, the most common symptoms were fatigue, fever, myalgia, cough and 
      anosmia/dysgeusia. During the post-acute phase, fatigue, shortness of breath, 
      concentration problems, headaches, trouble sleeping and anosmia/dysgeusia were 
      the most commonly reported symptoms, but a variety of others were endorsed by at 
      least some participants. Some experienced symptoms of depression, anxiety, and 
      post-traumatic stress, as well as difficulties with ambulation and performance of 
      usual activities. The median visual analogue scale value rating of general health 
      was lower at 4 and 8 months (80, interquartile range [IQR]: 70-90; and 80, IQR 
      75-90) compared to prior to COVID-19 (85; IQR 75-90). Biospecimens were collected 
      at nearly 600 participant-visits. CONCLUSION: Among a cohort of participants 
      enrolled in the post-acute phase of SARS-CoV-2 infection, we found many with 
      persistent physical symptoms through 8 months following onset of COVID-19 with an 
      impact on self-rated overall health. The presence of participants with and 
      without symptoms and ample biological specimens will facilitate study of PASC 
      pathogenesis. Similar evaluations in a population-representative sample will be 
      needed to estimate the population-level prevalence of PASC.
FAU - Peluso, Michael J
AU  - Peluso MJ
AD  - Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San 
      Francisco General Hospital, University of California, San Francisco, USA.
FAU - Kelly, J Daniel
AU  - Kelly JD
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
AD  - Department of Ophthalmology, University of California, San Francisco, USA.
FAU - Lu, Scott
AU  - Lu S
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Goldberg, Sarah A
AU  - Goldberg SA
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Davidson, Michelle C
AU  - Davidson MC
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Mathur, Sujata
AU  - Mathur S
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Durstenfeld, Matthew S
AU  - Durstenfeld MS
AD  - Division of Cardiology, Zuckerberg San Francisco General Hospital, University of 
      California, San Francisco, USA.
FAU - Spinelli, Matthew A
AU  - Spinelli MA
AD  - Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San 
      Francisco General Hospital, University of California, San Francisco, USA.
FAU - Hoh, Rebecca
AU  - Hoh R
AD  - Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San 
      Francisco General Hospital, University of California, San Francisco, USA.
FAU - Tai, Viva
AU  - Tai V
AD  - Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San 
      Francisco General Hospital, University of California, San Francisco, USA.
FAU - Fehrman, Emily A
AU  - Fehrman EA
AD  - Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San 
      Francisco General Hospital, University of California, San Francisco, USA.
FAU - Torres, Leonel
AU  - Torres L
AD  - Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San 
      Francisco General Hospital, University of California, San Francisco, USA.
AD  - Division of Experimental Medicine, University of California, San Francisco, USA.
FAU - Hernandez, Yanel
AU  - Hernandez Y
AD  - Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San 
      Francisco General Hospital, University of California, San Francisco, USA.
FAU - Williams, Meghann C
AU  - Williams MC
AD  - Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San 
      Francisco General Hospital, University of California, San Francisco, USA.
FAU - Arreguin, Mireya I
AU  - Arreguin MI
AD  - Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San 
      Francisco General Hospital, University of California, San Francisco, USA.
FAU - Bautista, Jennifer A
AU  - Bautista JA
AD  - Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San 
      Francisco General Hospital, University of California, San Francisco, USA.
FAU - Ngo, Lynn H
AU  - Ngo LH
AD  - Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San 
      Francisco General Hospital, University of California, San Francisco, USA.
FAU - Deswal, Monika
AU  - Deswal M
AD  - Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San 
      Francisco General Hospital, University of California, San Francisco, USA.
FAU - Munter, Sadie E
AU  - Munter SE
AD  - Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San 
      Francisco General Hospital, University of California, San Francisco, USA.
AD  - Division of Experimental Medicine, University of California, San Francisco, USA.
FAU - Martinez, Enrique O
AU  - Martinez EO
AD  - Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San 
      Francisco General Hospital, University of California, San Francisco, USA.
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Anglin, Khamal A
AU  - Anglin KA
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Romero, Mariela D
AU  - Romero MD
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Tavs, Jacqueline
AU  - Tavs J
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Rugart, Paulina R
AU  - Rugart PR
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Chen, Jessica Y
AU  - Chen JY
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
AD  - Division of Experimental Medicine, University of California, San Francisco, USA.
FAU - Sans, Hannah M
AU  - Sans HM
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Murray, Victoria W
AU  - Murray VW
AD  - Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San 
      Francisco General Hospital, University of California, San Francisco, USA.
FAU - Ellis, Payton K
AU  - Ellis PK
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Donohue, Kevin C
AU  - Donohue KC
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Massachi, Jonathan A
AU  - Massachi JA
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Weiss, Jacob O
AU  - Weiss JO
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Mehdi, Irum
AU  - Mehdi I
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Pineda-Ramirez, Jesus
AU  - Pineda-Ramirez J
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Tang, Alex F
AU  - Tang AF
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Wenger, Megan
AU  - Wenger M
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Assenzio, Melissa
AU  - Assenzio M
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Yuan, Yan
AU  - Yuan Y
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Krone, Melissa
AU  - Krone M
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
FAU - Rutishauser, Rachel L
AU  - Rutishauser RL
AD  - Division of Experimental Medicine, University of California, San Francisco, USA.
FAU - Rodriguez-Barraquer, Isabel
AU  - Rodriguez-Barraquer I
AD  - Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San 
      Francisco General Hospital, University of California, San Francisco, USA.
FAU - Greenhouse, Bryan
AU  - Greenhouse B
AD  - Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San 
      Francisco General Hospital, University of California, San Francisco, USA.
FAU - Sauceda, John A
AU  - Sauceda JA
AD  - Center for AIDS Prevention Studies, University of California, San Francisco, USA.
FAU - Gandhi, Monica
AU  - Gandhi M
AD  - Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San 
      Francisco General Hospital, University of California, San Francisco, USA.
FAU - Hsue, Priscilla Y
AU  - Hsue PY
AD  - Division of Cardiology, Zuckerberg San Francisco General Hospital, University of 
      California, San Francisco, USA.
FAU - Henrich, Timothy J
AU  - Henrich TJ
AD  - Division of Experimental Medicine, University of California, San Francisco, USA.
FAU - Deeks, Steven G
AU  - Deeks SG
AD  - Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San 
      Francisco General Hospital, University of California, San Francisco, USA.
FAU - Martin, Jeffrey N
AU  - Martin JN
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, USA.
LA  - eng
GR  - R01 AI158013/AI/NIAID NIH HHS/United States
GR  - T32 AI060530/AI/NIAID NIH HHS/United States
GR  - K23 AI146268/AI/NIAID NIH HHS/United States
GR  - K24 AI112393/AI/NIAID NIH HHS/United States
GR  - P30 AI027763/AI/NIAID NIH HHS/United States
PT  - Preprint
DEP - 20210312
PL  - United States
TA  - medRxiv
JT  - medRxiv : the preprint server for health sciences
JID - 101767986
UIN - Open Forum Infect Dis. 2021 Dec 21;9(2):ofab640. PMID: 35106317
PMC - PMC7987054
EDAT- 2021/03/25 06:00
MHDA- 2021/03/25 06:01
PMCR- 2021/03/23
CRDT- 2021/03/24 06:50
PHST- 2021/03/24 06:50 [entrez]
PHST- 2021/03/25 06:00 [pubmed]
PHST- 2021/03/25 06:01 [medline]
PHST- 2021/03/23 00:00 [pmc-release]
AID - 2021.03.11.21252311 [pii]
AID - 10.1101/2021.03.11.21252311 [doi]
PST - epublish
SO  - medRxiv [Preprint]. 2021 Mar 12:2021.03.11.21252311. doi: 
      10.1101/2021.03.11.21252311.